CIK 0001130598 · Non-accelerated filer<br>Smaller reporting company
Traws Pharma, Inc.
Sign in to watch- Ticker
- TRAW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 267-759-3680
- Business address
- 12 PENNS TRAIL, NEWTOWN, PA, 18940
- Former names
- Onconova Therapeutics, Inc., ONCONOVA THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-02 | TPAV, LLC 10% owner | Other disposition · Series C Preferred Stock | −2,263.75 | 0 | ||
| 2025-02-18 | CAUTREELS WERNER Chief Executive Officer | Option exercise | +96,348 | $0.01 | $963 | 104,348 |
| 2025-02-18 | CAUTREELS WERNER Chief Executive Officer | Option exercise · Pre-Funded Warrant (right to buy) | −96,348 | 0 | ||
| 2024-12-29 | ORBIMED ADVISORS LLC 10% owner | Purchase · Pre-Funded Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | ORBIMED ADVISORS LLC 10% owner | Purchase · Series A Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | CAUTREELS WERNER Chief Executive Officer | Purchase · Pre-Funded Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | CAUTREELS WERNER Chief Executive Officer | Purchase · Series A Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | TPAV, LLC 10% owner | Purchase · Pre-Funded Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | TPAV, LLC 10% owner | Purchase · Series A Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | Savchuk Nikolay Chief Operating Officer | Purchase · Pre-Funded Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-12-29 | Savchuk Nikolay Chief Operating Officer | Purchase · Series A Warrant (right to buy) | +96,348 | 96,348 | ||
| 2024-09-16 | Greenwood Luba Director | Grant or award · Stock Option (Right to Purchase) | +164,000 | 164,000 | ||
| 2024-06-18 | Guerin Mark Patrick CFO | Shares withheld for taxes | −2,221 | $0.47 | $1K | 39,255 |
| 2024-06-18 | Guerin Mark Patrick CFO | Option exercise · Restricted Stock Units | −5,500 | 5,500 | ||
| 2024-06-10 | Guerin Mark Patrick CFO | Option exercise | +5,500 | 41,476 | ||
| 2024-04-01 | Dukes Iain D. Executive Chairman | Grant or award | +67,500 | 134,187 | ||
| 2024-04-01 | Savchuk Nikolay Chief Operating Officer | Grant or award | +67,500 | 134,187 | ||
| 2024-04-01 | Redfield Robert Acting Chief Medical Officer | Grant or award | +97,500 | 97,500 | ||
| 2024-04-01 | Pauza Charles David Chief Science Officer Virology | Grant or award | +97,500 | 97,500 | ||
| 2024-04-01 | Pauza Charles David Chief Science Officer Virology | Grant or award · Stock Option (right to purchase) | +333,136 | 333,136 |
Page 4 of 9 · 170 trades